Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA
Open accessAbstract
// Young Kwang Chae 1, 2, 3, * , Andrew A. Davis 2, * , Benedito A. Carneiro 1, 2, 3 , Sunandana Chandra 1, 2, 3 , Nisha Mohindra 2, 3 , Aparna Kalyan 1, 2, 3 , Jason Kaplan 1, 2, 3 , Maria Matsangou 1, 2, 3 , Sachin Pai 1, 3 , Ricardo Costa 1, 3 , Borko Jovanovic 2, 3 , Massimo Cristofanilli 1, 2, 3 , Leonidas C. Platanias 1, 2, 3, 4 , Francis J. Giles 1, 2, 3 1 Developmental Therapeutics Program of Division of Hematology Oncology, Northwestern University, Chicago, IL, USA 2 Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA 3 Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA 4 Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, IL, USA * These authors contributed equally to this work Correspondence to: Young Kwang Chae, email: young.chae@northwestern.edu Keywords: next-generation sequencing, cell-free DNA, genomic alterations, metastatic disease, lung cancer Received: April 14, 2016 Accepted: August 10, 2016 Published: August 30, 2016 ABSTRACT Genomic analysis of tumor tissue is the standard technique for identifying DNA alterations in malignancies. Genomic analysis of circulating tumor cell-free DNA (cfDNA) represents a relatively non-invasive method of assessing genomic alterations using peripheral blood. We compared the concordance of genomic alterations between cfDNA and tissue biopsies in this retrospective study. Twenty-eight patients with advanced solid tumors with paired next-generation sequencing tissue and cfDNA biopsies were identified. Sixty-five genes were common to both assays. Concordance was defined as the presence or absence of the identical genomic alteration(s) in a single gene on both molecular platforms. Including all aberrations, the average number of alterations per patient for tissue and cfDNA analysis was 4.82 and 2.96, respectively. When eliminating alterations not detectable in the cfDNA assay, mean number of alterations for tissue and cfDNA was 3.21 and 2.96, respectively. Overall, concordance was 91.9–93.9%. However, the concordance rate decreased to 11.8–17.1% when considering only genes with reported genomic alterations in either assay. Over 50% of mutations detected in either technique were not detected using the other biopsy technique, indicating a potential complementary role of each assay. Across 5 genes ( TP53, EGFR, KRAS, APC, CDKN2A ), sensitivity and specificity were 59.1% and 94.8%, respectively. Potential explanations for the lack of concordance include differences in assay platform, spatial and temporal factors, tumor heterogeneity, interval treatment, subclones, and potential germline DNA contamination. These results highlight the importance of prospective studies to evaluate concordance of genomic findings between distinct platforms that ultimately may inform treatment decisions.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Concordance of tissue mutations detected in plasma samples can be approximately 90% in late-stage lung cancer.
“Concordance of tissue mutations detected in plasma samples can be ~90% in late-stage lung cancer71,72.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · see citing works
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067 · see citing works
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338 · see citing works
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210 · see citing works
Jahr, S., Hentze, H., Englisch, S., Hardt, D., Fackelmayer, F. O., Hesch, R. D., & Knippers, R. (2001) · PubMed · Cited by 2,188 · see citing works
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 2× · see citing works
“Of these, 29 patients had comprehensive tissue NGS testing (FoundationOne) commercially performed by Foundation Medicine (Cambridge, MA) [26].”
MethodThe Life History of 21 Breast Cancers
Nik-Zainal, S., Van Loo, P., Wedge, D. C., Alexandrov, L. B., Greenman, C. D., Lau, K. W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.023 · Cited by 1,443 · see citing works
Systematic pan-cancer analysis of tumour purity
Aran, D., Sirota, M., & Butte, A. J. (2015) · Nature Communications · doi:10.1038/ncomms9971 · Cited by 1,206 · see citing works
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., et al. (2014) · Science · doi:10.1126/science.1253462 · Cited by 1,117 · see citing works
Clonal evolution in breast cancer revealed by single nucleus genome sequencing
Wang, Y., Waters, J., Leung, M. L., Unruh, A., Roh, W., Shi, X., Chen, K., Scheet, P., Vattathil, S., Liang, H., et al. (2014) · Nature · doi:10.1038/nature13600 · Cited by 1,029 · see citing works
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., et al. (2014) · Science · doi:10.1126/science.1256930 · Cited by 965 · see citing works
Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574 · see citing works
Sacher, A. G., Paweletz, C. P., Dahlberg, S. E., Alden, R. S., O’Connell, A., Feeney, N. B., Mach, S. L., Janne, P. A., & Oxnard, G. R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0173 · Cited by 573 · see citing works
Mok, T., Wu, Y.-L., Lee, J. S., Yu, C.-J., Sriuranpong, V., Sandoval-Tan, J., Ladrera, G., Thongprasert, S., Srimuninnimit, V., Liao, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2594 · Cited by 468 · see citing works
Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?
Overman, M. J., Modak, J. M., Kopetz, S., Murthy, R., Yao, J. C., Hicks, M. E., Abbruzzese, J. L., & Tam, A. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1718 · Cited by 315 · see citing works
Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas
Zill, O. A., Greene, C., Sebisanovic, D., Siew, L. M., Leng, J., Vu, M., Hendifar, A. E., Wang, Z., Atreya, C. E., Kelley, R. K., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0274 · Cited by 282 · see citing works
The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients
Elshimali, Y., Khaddour, H., Sarkissyan, M., Wu, Y., & Vadgama, J. V. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140918925 · Cited by 236 · see citing works
Hiley, C. T., de Bruin, E. C., McGranahan, N., & Swanton, C. (2014) · Genome biology · doi:10.1186/s13059-014-0453-8 · Cited by 221 · see citing works
Circulating tumour cells and cell-free DNA as tools for managing breast cancer
Mattos‐Arruda, L. D., Cortés, J., Santarpia, L., Vivancos, A. P., Tabernero, J. M., Reis-Filho, J. S., & Seoane, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.80 · Cited by 175 · see citing works
Schwaederle, M. C., Husain, H., Fanta, P. T., Piccioni, D. E., Kesari, S., Schwab, R. B., Banks, K. C., Lanman, R. B., Talasaz, A. H., Parker, B. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7110 · Cited by 150 · see citing works
Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
Birkbak, N. J., Kochupurakkal, B. S., Izarzugaza, J. M. G., Eklund, A. C., Li, Y., Liu, J. F., Szállási, Z., Matulonis, U. A., Richardson, A. L., Iglehart, J. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080023 · Cited by 141 · see citing works
Jovelet, C., Ileana, E. E., Deley, M. L., Motté, N., Rosellini, S., Romero, A., Lefèbvre, C., Pedrero, M., Pata-Merci, N., Droin, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2470 · Cited by 124 · see citing works
Jankú, F., Angenendt, P., Tsimberidou, A. M., Fu, S., Naing, A., Falchook, G. S., Hong, D. S., Holley, V. R., Cabrilo, G., Wheler, J. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3373 · Cited by 93 · see citing works
Kim, S. T., Lee, W.-S., Lanman, R. B., Mortimer, S., Zill, O. A., Kim, S. H., Jang, K. T., Kim, S.-H., Park, S. H., Park, J. O., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5465 · Cited by 85 · see citing works
BRAF mutation testing with a rapid, fully integrated molecular diagnostics system
Jankú, F., Claes, B., Huang, H. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4723 · Cited by 49 · see citing works
Clinical Application of Liquid Biopsies
Williams, P. M., & Conley, B. A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0240 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Palma, G., Khurshid, F., Lu, K., Woodward, B., & Husain, H. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00237-5 · Cited by 72 · see citing works
Gupta, R., Othman, T., Chen, C., Sandhu, J., Ouyang, C., & Fakih, M. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0441 · Cited by 70 · see citing works
- Authors
- Chae, Y. K., Davis, A. A., Carneiro, B. A., Chandra, S., Mohindra, N., Kalyan, A., Kaplan, J., Matsangou, M., Pai, S., Costa, R., Jovanovic, B., Cristofanilli, M., Platanias, L. C., & Giles, F. J.
- Affiliations
- Northwestern University (US)
- Corresponding author
- Chae, Young Kwang
- Davis, Andrew A.
- ORCID
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-08-30
- Volume
- 7
- Issue
- 40
- Pages
- 65364-65373
- ISSN
- 1949-2553 (ISSN-L)
- PMC
- PMC5323161
- OpenAlex
- W2513731937
- Cited by
- 110
- References
- 30
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 10 · 2023: 12 · 2022: 7 · 2021: 14 · 2020: 8 · 2019: 17 · 2018: 16 · 2017: 20 · 2016: 2
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Oncotarget (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30CA060553)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- cell-free DNA, tumor genomic alterations, tissue biopsy comparison, concordance, liquid biopsy, metastatic solid tumors, lung cancer, next-generation sequencing, non-invasive cancer detection, targeted therapy biomarkers, treatment response monitoring, KRAS, BRAF, anaplastic lymphoma kinase
- MeSH terms
- Cell-Free Nucleic Acids, Adenocarcinoma, Biopsy, Female, Humans, Lung Neoplasms, Male, Mutation, Sensitivity and Specificity, Reproducibility of Results, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Genome, Cyclin-Dependent Kinase Inhibitor p16, Adenomatous Polyposis Coli Protein, Cyclin-Dependent Kinase Inhibitor p18, Pathology, Molecular, High-Throughput Nucleotide Sequencing, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
